Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.
Julie Ryan WolfAnita ChenJill WieserBrad JohnsonLauren BaughmanGayin LeeEleanor PopeAbigail FrancoTanzy LoveLisa A BeckPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Our results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.